Introduction: SLN is alternative to traditional colloidal carrier systems such as emulsion, liposome, and polymeric micro-and nanoparticles. They are highly biocompatible, have low cytotoxicity, target specific, scalability, prolonged drug release, and ease of production in industrial scale. Objective: Current study aims to formulate and characterize Nilotinib-loaded solid lipid nanoparticles (SLNs) carrier system. Methods: About 17 SLN formulations were fabricated employing hot emulsification/ ultrasonication technique. A full factorial design (33) was employed for formulation batches (i.e.,17 formulations) in which 3 factors namely lipid, surfactant and co-surfactant were tested at 3 levels of concentration. The effect of different levels of factors was evaluated at the particle size of resultant formulation, entrapment efficiency and % cumulative drug released. Kinetic model fitting for all nilotinib SLN formulations was done to interpret the release rate from the SLN. Optimized formulation was subjected for FTIR, SEM and stability studies. Results: The mean particle size, PDI, zeta potential, entrapment efficiency (EE), content uniformity and in-vitro drug release profile of optimized nilotinib-loaded SLNs (NF12) were found to be 132.11 __ampersandsignplusmn; 3.47nm, 0.128 __ampersandsignplusmn; 0.02, -18.02 __ampersandsignplusmn; 2.17mV, 84.12__ampersandsignplusmn;2.66%, 98.96__ampersandsignplusmn;1.23% and 98.86__ampersandsignplusmn;2.12% respectively. The release kinetics suggest that drug release followed zero-order and release was anomalous non- fickian diffusion super case II transport. The FTIR studies revealed no incompatibilities between the drug and excipient, and SEM images showed that the nanoparticles appeared to be more porous and spherical in shape. The formulation was shown to be stable over a period of six months by stability studies. Conclusion: According to the results, the method of SLN preparation proposed in this study could be considered as the most suitable method for generating colloidal carriers loaded with nilotinib.